Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody
The purpose of this study is to assess the safety and tolerability of Hu5F9-G4 in participants with solid tumors.
Solid Tumor
DRUG: Hu5F9-G4
Safety and Tolerability of Hu5F9-G4, The CTCAE criteria will be used to assess adverse events on this trial., The first 28 days on study, for determination of Dose Limiting Toxicities
This is a first-in-human, first-in-class, escalating dose trial of an antibody that inhibits an anti-apoptotic signal in human macrophages. The major aims of the study are to define the safety profile of this new drug, and to determine a recommended dose and schedule for potential additional trials.